Multiple symmetric lipomatosis (Launois-Bensaude syndrome): effect of oral salbutamol.
A 65-year-old Kenyan Asian developed rapidly progressive multiple symmetrical lipomatosis over 8 years. Noradrenaline infusion showed a normal response of plasma free fatty acids. In-vitro studies of the lipomatous tissue demonstrated intact lipolytic activities with a normal rate of free fatty acids release and cyclic AMP accumulation with or without isoprenaline and fenoterol stimulation. A clinical trial of oral salbutamol, a beta 2-agonist, was performed with significant therapeutic effect. The body fat mass showed a reversal of the rapid progression while on the treatment, associated with an increase in the resting metabolic rate.
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D000242:Cyclic AMP / Q000378:metabolism; D006801:Humans; D008066:Lipolysis / Q000187:drug effects; D008068:Lipomatosis / Q000188:drug therapy*; D008069:Lipomatosis, Multiple Symmetrical / Q000188:drug therapy* / Q000378:metabolism; D008297:Male
D000318:Adrenergic beta-Agonists; D000242:Cyclic AMP; D000420:Albuterol